(Stroke. 1997;28:2382-2389.)
© 1997 American Heart Association, Inc.
Articles |
From the Center for Outcomes Research and Evaluation, YaleNew Haven Hospital, New Haven, Conn (L.M.B., H.M.K.); Neurology Service, VA Connecticut Healthcare System, West Haven (L.M.B.); Yale Stroke Program, Department of Neurology (L.M.B.), Section of Chronic Disease Epidemiology, School of Epidemiology and Public Health (L.M.B., H.M.K.), and Department of Cardiology (H.M.K.), Yale University School of Medicine, New Haven, Conn; Connecticut Peer Review Organization, Middletown (L.M.B., H.M.K., J.M.S., M.R.); and Department of Cardiology (M.R.), University of Connecticut Health Sciences Center, Farmington.
Correspondence to Lawrence M. Brass, MD, Yale Stroke Program, Department of Neurology, LCI-700, Yale University School of Medicine, 15 York St, PO Box 208018, New Haven, CT 06520-8018. E-mail lawrence.brass{at}yale.edu
Background and Purpose Warfarin reduces the rate of stroke among patients with atrial fibrillation. We sought to determine warfarin use within a population sample of elderly patients with atrial fibrillation.
Methods The Connecticut Peer Review Organization conducted a
chart review of Medicare patients aged
65 years with a history of
atrial fibrillation before a hospitalization during the first 6 months
of 1994.
Results Among 488 patients (308 women; 457 white; 173 aged
85
years), 38% (184/488) had a relative contraindication to
anticoagulation (history of bleeding, dementia, alcohol use, falls,
cancer, or the need for nonsteroidal anti-inflammatory drugs). Among
the remaining patients (with known atrial fibrillation, but without a
contraindication), only 38% (117/304) had been prescribed warfarin. Of
those not prescribed warfarin, 63% (117/187) were also not taking
aspirin. There were 272 patients with at least one additional vascular
risk factor and no contraindication to anticoagulation. Among these
patients at moderate to high risk for stroke, anticoagulation had been
prescribed in 40% (109/272). Overall, among those not prescribed
warfarin, 58% (95/163) were not taking aspirin. Patients admitted with
a stroke were more likely to be significantly underanticoagulated (with
international normalized ratio <1.5) (43.5% versus 20.9% for those
without stroke; P<.005). Anticoagulation was most
effective for those with an international normalized ratio
2.0.
Conclusions Warfarin anticoagulation with atrial fibrillation, even among "ideal" candidates, appears dramatically underutilized. In addition, among those prescribed warfarin, patients are often undertreated. Increased warfarin use among patients with atrial fibrillation represents an excellent opportunity for stroke prevention in the elderly.
Key Words: anticoagulants atrial fibrillation stroke prevention warfarin
This article has been cited by other articles:
![]() |
D. E. Singer, Y. Chang, M. C. Fang, L. H. Borowsky, N. K. Pomernacki, N. Udaltsova, and A. S. Go Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?: The ATRIA Study Circ Cardiovasc Qual Outcomes, July 1, 2009; 2(4): 297 - 304. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Kanderian, A. M. Gillinov, G. B. Pettersson, E. Blackstone, and A. L. Klein Success of Surgical Left Atrial Appendage Closure: Assessment by Transesophageal Echocardiography J. Am. Coll. Cardiol., September 9, 2008; 52(11): 924 - 929. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 546S - 592S. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Nutescu ASHP Therapeutic Position Statement on Antithrombotic Therapy in Chronic Atrial Fibrillation Am. J. Health Syst. Pharm., November 1, 2007; 64(21): 2281 - 2291. [Full Text] [PDF] |
||||
![]() |
N. Anderson, R. Fuller, and N. Dudley 'Rules of thumb' or reflective practice? Understanding senior physicians' decision-making about anti-thrombotic usage in atrial fibrillation QJM, May 1, 2007; 100(5): 263 - 269. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Sick, G. Schuler, K. E. Hauptmann, E. Grube, S. Yakubov, Z. G. Turi, G. Mishkel, S. Almany, and D. R. Holmes Initial Worldwide Experience With the WATCHMAN Left Atrial Appendage System for Stroke Prevention in Atrial Fibrillation J. Am. Coll. Cardiol., April 3, 2007; 49(13): 1490 - 1495. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rash, T. Downes, R. Portner, W. W. Yeo, N. Morgan, and K. S. Channer A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO) Age Ageing, March 1, 2007; 36(2): 151 - 156. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Dagres, R. Nieuwlaat, P. E. Vardas, D. Andresen, S. Levy, S. Cobbe, D. Th. Kremastinos, G. Breithardt, D. V. Cokkinos, and H. J.G.M. Crijns Gender-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe: A Report From the Euro Heart Survey on Atrial Fibrillation J. Am. Coll. Cardiol., February 6, 2007; 49(5): 572 - 577. [Abstract] [Full Text] [PDF] |
||||
![]() |
L Kalra, G Y H Lip, and on behalf of the Guideline Development Group for t Antithrombotic treatment in atrial fibrillation Heart, January 1, 2007; 93(1): 39 - 44. [Full Text] [PDF] |
||||
![]() |
L. Friberg, N. Hammar, M. Ringh, H. Pettersson, and M. Rosenqvist Stroke prophylaxis in atrial fibrillation: who gets it and who does not?: Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study) Eur. Heart J., August 2, 2006; 27(16): 1954 - 1964. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Circulation, June 20, 2006; 113(24): e873 - e923. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Stroke, June 1, 2006; 37(6): 1583 - 1633. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Hylek, J. D'Antonio, C. Evans-Molina, C. Shea, L. E. Henault, and S. Regan Translating the Results of Randomized Trials into Clinical Practice: The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation Stroke, April 1, 2006; 37(4): 1075 - 1080. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Miyasaka, M. E. Barnes, B. J. Gersh, S. S. Cha, J. B. Seward, K. R. Bailey, T. Iwasaka, and T. S.M. Tsang Time Trends of Ischemic Stroke Incidence and Mortality in Patients Diagnosed With First Atrial Fibrillation in 1980 to 2000: Report of a Community-Based Study Stroke, November 1, 2005; 36(11): 2362 - 2366. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Ostermayer, M. Reisman, P. H. Kramer, R. V. Matthews, W. A. Gray, P. C. Block, H. Omran, A. L. Bartorelli, P. Della Bella, C. Di Mario, et al. Percutaneous Left Atrial Appendage Transcatheter Occlusion (PLAATO System) to Prevent Stroke in High-Risk Patients With Non-Rheumatic Atrial Fibrillation: Results From the International Multi-Center Feasibility Trials J. Am. Coll. Cardiol., July 5, 2005; 46(1): 9 - 14. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Garcia, S. Regan, M. Crowther, R. A. Hughes, and E. M. Hylek Warfarin Maintenance Dosing Patterns in Clinical Practice: Implications for Safer Anticoagulation in the Elderly Population Chest, June 1, 2005; 127(6): 2049 - 2056. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Lim, C. Roychoudhury, P. L. Baker, E. Bossone, and R. H. Mehta Differences in quality of care among patients hospitalized with atrial fibrillation as primary or secondary cause for admission Int. J. Qual. Health Care, June 1, 2005; 17(3): 255 - 258. [Abstract] [Full Text] [PDF] |
||||
![]() |
R Katira, A Chauhan, and R S More Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation Postgrad. Med. J., June 1, 2005; 81(956): 370 - 375. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Hackam, A. Kopp, and D. A. Redelmeier Prognostic Implications of Warfarin Cessation After Major Trauma: A Population-Based Cohort Analysis Circulation, May 3, 2005; 111(17): 2250 - 2256. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Reynolds, K. Fahrbach, O. Hauch, G. Wygant, R. Estok, C. Cella, and L. Nalysnyk Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation: A Systematic Review and Metaanalysis Chest, December 1, 2004; 126(6): 1938 - 1945. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Teng, T. C. Sarich, U. G. Eriksson, J. E. Hamer, S. Gillette, K.-M. Schutzer, G. F. Carlson Jr, and P. R. Kowey A Pharmacokinetic Study of the Combined Administration of Amiodarone and Ximelagatran, an Oral Direct Thrombin Inhibitor J. Clin. Pharmacol., September 1, 2004; 44(9): 1063 - 1071. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Singer, G. W. Albers, J. E. Dalen, A. S. Go, J. L. Halperin, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 429S - 456S. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Volpato, C. Maraldi, A. Ble, M. Ranzini, A. Rita Atti, L. J. Dominguez, M. Barbagallo, R. Fellin, and G. Zuliani Prescription of Antithrombotic Therapy in Older Patients Hospitalized for Transient Ischemic Attack and Ischemic Stroke: The GIFA Study Stroke, April 1, 2004; 35(4): 913 - 917. [Abstract] [Full Text] [PDF] |
||||
![]() |
J S Steinberg Atrial fibrillation: an emerging epidemic? Heart, March 1, 2004; 90(3): 239 - 240. [Full Text] [PDF] |
||||
![]() |
G.Q. Villani, M. Piepoli, P.E. Villani, and A. Capucci Anticoagulation in atrial fibrillation: what is certain and what is to come Eur. Heart J. Suppl., September 1, 2003; 5(suppl_H): H45 - H50. [Abstract] [PDF] |
||||
![]() |
R. S. Stafford and D. C. Radley The underutilization of cardiacmedications of proven benefit, 1990 to 2002 J. Am. Coll. Cardiol., January 1, 2003; 41(1): 56 - 61. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Koelling and K. A. Eagle Measuring quality of outpatient cardiovascular care J. Am. Coll. Cardiol., January 1, 2003; 41(1): 69 - 72. [Full Text] [PDF] |
||||
![]() |
P J Devereaux, D. R Anderson, M. J Gardner, W. Putnam, G. J Flowerdew, B. F Brownell, S. Nagpal, J. L Cox, and T. Fahey Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study Commentary: Varied preferences reflect the reality of clinical practice BMJ, November 24, 2001; 323(7323): 1218 - 1218. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. McCormick, J. H. Gurwitz, R. J. Goldberg, R. Becker, J. P. Tate, A. Elwell, and M. J. Radford Prevalence and Quality of Warfarin Use for Patients With Atrial Fibrillation in the Long-term Care Setting Arch Intern Med, November 12, 2001; 161(20): 2458 - 2463. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Wehinger, C. Stollberger, T. Langer, B. Schneider, and J. Finsterer Evaluation of Risk Factors for Stroke/Embolism and of Complications Due to Anticoagulant Therapy in Atrial Fibrillation Stroke, October 1, 2001; 32(10): 2246 - 2252. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Shinokawa, T. Hirai, S. Takashima, T. Kameyama, K. Nakagawa, H. Asanoi, and H. Inoue A Transesophageal Echocardiographic Study on Risk Factors for Stroke in Elderly Patients With Atrial Fibrillation : A Comparison With Younger Patients Chest, September 1, 2001; 120(3): 840 - 846. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Sappok, A. Faulstich, E. Stuckert, H. Kruck, P. Marx, and H.-C. Koennecke Compliance With Secondary Prevention of Ischemic Stroke: A Prospective Evaluation Stroke, August 1, 2001; 32(8): 1884 - 1889. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Albers, J. E. Dalen, A. Laupacis, W. J. Manning, P. Petersen, and D. E. Singer Antithrombotic Therapy in Atrial Fibrillation Chest, January 1, 2001; 119 (2009): 194S - 206S. [Full Text] [PDF] |
||||
![]() |
D A Fitzmaurice, J Mant, E T Murray, F D R Hobbs, N. Oswald, M D Oliver, A. Ono, G. Bellelli, A. Bianchetti, and M. Trabucchi Anticoagulation to prevent stroke in atrial fibrillation BMJ, November 4, 2000; 321(7269): 1156 - 1156. [Full Text] |
||||
![]() |
K N Vemmos, M L Bots, P K Tsibouris, V P Zis, C E Takis, D E Grobbee, and S Stamatelopoulos Prognosis of stroke in the south of Greece: 1 year mortality, functional outcome and its determinants: the Arcadia Stroke Registry J. Neurol. Neurosurg. Psychiatry, November 1, 2000; 69(5): 595 - 600. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. B. Goldstein, J. Bian, G. P. Samsa, A. J. Bonito, L. J. Lux, and D. B. Matchar New Transient Ischemic Attack and Stroke: Outpatient Management by Primary Care Physicians Arch Intern Med, October 23, 2000; 160(19): 2941 - 2946. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Holloway, C. Benesch, and S. R. Rush Stroke prevention: Narrowing the evidence-practice gap Neurology, May 23, 2000; 54(10): 1899 - 1906. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Kalra, G. Yu, I. Perez, A. Lakhani, and N. Donaldson Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness BMJ, May 6, 2000; 320(7244): 1236 - 1239. [Abstract] [Full Text] |
||||
![]() |
B. F. Gage, M. Boechler, A. L. Doggette, G. Fortune, G. C. Flaker, M. W. Rich, and M. J. Radford Adverse Outcomes and Predictors of Underuse of Antithrombotic Therapy in Medicare Beneficiaries With Chronic Atrial Fibrillation Stroke, April 1, 2000; 31(4): 822 - 827. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. N. Kernan, C. M. Viscoli, L. M. Brass, R. W. Makuch, P. M. Sarrel, and R. I. Horwitz Blood Pressure Exceeding National Guidelines Among Women After Stroke Stroke, February 1, 2000; 31(2): 415 - 419. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hillen, R. Dundas, E. Lawrence, J. A. Stewart, A. G. Rudd, and C. D. A. Wolfe Antithrombotic and Antihypertensive Management 3 Months After Ischemic Stroke : A Prospective Study in an Inner City Population Stroke, February 1, 2000; 31(2): 469 - 475. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Bungard, W. A. Ghali, K. K. Teo, F. A. McAlister, and R. T. Tsuyuki Why Do Patients With Atrial Fibrillation Not Receive Warfarin? Arch Intern Med, January 10, 2000; 160(1): 41 - 46. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Carlsson, S. Miketic, G. Dees, S. Haun, A. Cuneo, and U. Tebbe Stroke prevention practices in patients with atrial fibrillation and pacemaker therapy: Evidence for under-use of anticoagulation Europace, January 1, 2000; 2(2): 115 - 118. [Abstract] [PDF] |
||||
![]() |
L. B. Goldstein, L. A. Hey, and R. Laney North Carolina Stroke Prevention and Treatment Facilities Survey : Statewide Availability of Programs and Services Stroke, January 1, 2000; 31(1): 66 - 70. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Go, E. M. Hylek, L. H. Borowsky, K. A. Phillips, J. V. Selby, and D. E. Singer Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study Ann Intern Med, December 21, 1999; 131(12): 927 - 934. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Cox, N. Ad, and T. Palazzo IMPACT OF THE MAZE PROCEDURE ON THE STROKE RATE IN PATIENTS WITH ATRIAL FIBRILLATION J. Thorac. Cardiovasc. Surg., November 1, 1999; 118(5): 833 - 840. [Abstract] [Full Text] [PDF] |
||||
![]() |
N M Al-Saady, O A Obel, and A J Camm Left atrial appendage: structure, function, and role in thromboembolism Heart, November 1, 1999; 82(5): 547 - 554. [Abstract] [Full Text] |
||||
![]() |
D Deplanque, F Corea, C Arquizan, L Parnetti, J L Mas, V Gallai, D Leys, and the SAFE I Study Investigators Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand? Heart, November 1, 1999; 82(5): 563 - 569. [Abstract] [Full Text] |
||||
![]() |
I Perez, A Melbourn, and L Kalra Use of antithrombotic measures for stroke prevention in atrial fibrillation Heart, November 1, 1999; 82(5): 570 - 574. [Abstract] [Full Text] |
||||
![]() |
J. J. Caro, K. M. Flegel, M.-E. Orejuela, H. E. Kelley, J. L. Speckman, and K. Migliaccio-Walle Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice Can. Med. Assoc. J., September 1, 1999; 161(5): 493 - 497. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Connolly Preventing stroke in atrial fibrillation: Why are so many eligible patients not receiving anticoagulant therapy? Can. Med. Assoc. J., September 1, 1999; 161(5): 533 - 534. [Full Text] [PDF] |
||||
![]() |
N. L. Smith, B. M. Psaty, C. D. Furberg, R. White, J. A. C. Lima, A. B. Newman, and T. A. Manolio Temporal Trends in the Use of Anticoagulants Among Older Adults With Atrial Fibrillation Arch Intern Med, July 26, 1999; 159(14): 1574 - 1578. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Kalra, I. Perez, and A. Melbourn Risk Assessment and Anticoagulation for Primary Stroke Prevention in Atrial Fibrillation Stroke, June 1, 1999; 30(6): 1218 - 1222. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. N. Vemmos, M. L. Bots, P. K. Tsibouris, V. P. Zis, D. E. Grobbee, G. S. Stranjalis, and S. Stamatelopoulos Stroke Incidence and Case Fatality in Southern Greece : The Arcadia Stroke Registry Stroke, February 1, 1999; 30(2): 363 - 370. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Brass, H. M. Krumholz, J. D. Scinto, D. Mathur, and M. Radford Warfarin Use Following Ischemic Stroke Among Medicare Patients With Atrial Fibrillation Arch Intern Med, October 26, 1998; 158(19): 2093 - 2100. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Albers Choice of Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation: Warfarin, Aspirin, or Both? Arch Intern Med, July 27, 1998; 158(14): 1487 - 1491. [Full Text] [PDF] |
||||
![]() |
L. A. Simons, J. McCallum, Y. Friedlander, and J. Simons Risk Factors for Ischemic Stroke : Dubbo Study of the Elderly Stroke, July 1, 1998; 29(7): 1341 - 1346. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |